KR101281208B1 - 피브로넥틴 ｅｄ-ｂ에 대한 항체 ｌ１９ 및 인터루킨１２의 융합 단백질 - Google Patents

피브로넥틴 ｅｄ-ｂ에 대한 항체 ｌ１９ 및 인터루킨１２의 융합 단백질 Download PDF

Info

Publication number
KR101281208B1
KR101281208B1 KR1020077028774A KR20077028774A KR101281208B1 KR 101281208 B1 KR101281208 B1 KR 101281208B1 KR 1020077028774 A KR1020077028774 A KR 1020077028774A KR 20077028774 A KR20077028774 A KR 20077028774A KR 101281208 B1 KR101281208 B1 KR 101281208B1
Authority
KR
South Korea
Prior art keywords
conjugate
ser
scfv
subunit
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077028774A
Other languages
English (en)
Korean (ko)
Other versions
KR20080009161A (ko
Inventor
다리오 네리
베레나 가프너
코르넬리아 할린
Original Assignee
필로겐 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 필로겐 에스.피.에이. filed Critical 필로겐 에스.피.에이.
Publication of KR20080009161A publication Critical patent/KR20080009161A/ko
Application granted granted Critical
Publication of KR101281208B1 publication Critical patent/KR101281208B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
KR1020077028774A 2005-05-11 2006-05-03 피브로넥틴 ｅｄ-ｂ에 대한 항체 ｌ１９ 및 인터루킨１２의 융합 단백질 Expired - Fee Related KR101281208B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68010505P 2005-05-11 2005-05-11
US60/680,105 2005-05-11
PCT/EP2006/004114 WO2006119897A2 (en) 2005-05-11 2006-05-03 Fusion protein of antibody l19 against fibronectin ed-b and interleukin 12

Publications (2)

Publication Number Publication Date
KR20080009161A KR20080009161A (ko) 2008-01-24
KR101281208B1 true KR101281208B1 (ko) 2013-07-26

Family

ID=37027526

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077028774A Expired - Fee Related KR101281208B1 (ko) 2005-05-11 2006-05-03 피브로넥틴 ｅｄ-ｂ에 대한 항체 ｌ１９ 및 인터루킨１２의 융합 단백질

Country Status (14)

Country Link
US (1) US8455625B2 (https=)
EP (1) EP1891102B1 (https=)
JP (1) JP2008543278A (https=)
KR (1) KR101281208B1 (https=)
CN (1) CN101258162A (https=)
AT (1) ATE459648T1 (https=)
AU (1) AU2006246061A1 (https=)
BR (1) BRPI0609100A2 (https=)
CA (1) CA2607954A1 (https=)
DE (1) DE602006012667D1 (https=)
EA (1) EA011992B1 (https=)
ES (1) ES2341126T3 (https=)
MX (1) MX2007013875A (https=)
WO (1) WO2006119897A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019190022A1 (ko) * 2018-03-30 2019-10-03 한국과학기술원 단백질-단백질 결합체를 형성 매개 펩타이드 및 이를 이용한 단백질-단백질 결합체 형성 방법

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
CA2648484A1 (en) * 2006-05-08 2007-11-15 Philogen Spa Antibody-targeted cytokines for therapy
EP1925664A1 (en) 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
WO2008120101A2 (en) 2007-04-02 2008-10-09 Philogen S.P.A. The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
DK3281952T3 (da) 2007-10-30 2020-08-03 Philogen Spa Antigen, der er forbundet med reumatoid artritis
WO2009126725A1 (en) * 2008-04-09 2009-10-15 The Regents Of The University Of Michigan Method of modulating neovascularization
CA2747154C (en) 2008-12-19 2015-11-10 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
EP2461832B1 (en) 2009-08-05 2017-06-28 Philogen S.p.A. Targeting of bone marrow neovasculature
JP5764127B2 (ja) 2009-08-17 2015-08-12 ロシュ グリクアート アーゲー 標的化イムノコンジュゲート
RU2553333C2 (ru) 2009-12-14 2015-06-10 Сцил Протеинс Гмбх Способ идентификации гетеромультимерных модифицированных убиквитиновых белков со способностью связываться с лигандами
WO2012001196A2 (es) 2010-06-28 2012-01-05 Proyecto De Biomedicina Cima, S.L. Vectores alfavirales y usos de los mismos para la expresión de genes heterólogos
RU2429005C1 (ru) * 2010-10-07 2011-09-20 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН Способ стимуляции противоопухолевой активности цитотоксических эффекторов иммунной системы
SG192673A1 (en) 2011-02-10 2013-09-30 Roche Glycart Ag Mutant interleukin-2 polypeptides
KR20130118941A (ko) 2011-02-10 2013-10-30 로슈 글리카트 아게 면역치료법
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CA2837804C (en) 2011-06-15 2018-03-20 Scil Proteins Gmbh Dimeric binding proteins based on modified ubiquitins
WO2012171541A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
ES2872964T3 (es) 2011-07-27 2021-11-03 Philogen Spa Inmunoconjugado de IL-12
CA2849033C (en) * 2011-09-26 2020-05-05 Philogen S.P.A. Immunocytokine combination therapy
EP2861616A1 (en) 2012-06-13 2015-04-22 Scil Proteins GmbH Human fusion proteins comprising single chain tnfalpha and targeting domains
ES2743423T3 (es) 2012-10-03 2020-02-19 Philogen Spa Conjugado de anticuerpos para su uso en el tratamiento de una enfermedad inflamatoria intestinal
WO2014094799A1 (en) 2012-12-19 2014-06-26 Scil-Proteins-Gmbh Ubiquitin moieties as a means for prolonging serum half-life
WO2014182532A1 (en) * 2013-05-07 2014-11-13 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Mesothelin-specific immunocytokine and use thereof
JP2017501712A (ja) * 2013-12-18 2017-01-19 イントレキソン コーポレーション 単鎖ｉｌ−１２核酸、ポリペプチド、およびそれらの使用
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
JP6738340B2 (ja) 2015-02-06 2020-08-12 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ 新規なｅｇｆｒ結合タンパク質
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
JP6856938B2 (ja) 2015-07-16 2021-04-14 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ 新規な免疫グロブリン結合タンパク質およびアフィニティ精製におけるそれらの使用
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
CR20180087A (es) 2015-07-16 2018-05-14 Philogen Spa Inmunoconjugados de il22
WO2017013136A1 (en) 2015-07-20 2017-01-26 Scil Proteins Gmbh Novel binding proteins based on di-ubiquitin muteins and methods for generation
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
US11813336B2 (en) 2016-05-04 2023-11-14 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
US12304935B2 (en) 2016-07-29 2025-05-20 Juno Therapeutics, Inc. Immunomodulatory polypeptides and related compositions and methods
CN109963864B (zh) 2016-08-11 2024-01-02 瑞普利金公司 用于亲和色谱的碱性稳定性fc结合蛋白
ES3007557T3 (en) * 2016-10-17 2025-03-20 Pfizer Anti-edb antibodies and antibody-drug conjugates
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
CN108250302A (zh) * 2016-12-29 2018-07-06 天津天锐生物科技有限公司 一种多功能蛋白质
JP2020530280A (ja) 2017-07-03 2020-10-22 トルク セラピューティクス， インコーポレイテッド 免疫刺激性融合分子およびその使用
US11414466B2 (en) 2017-11-07 2022-08-16 Navigo Proteins Gmbh Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer
TWI844524B (zh) * 2018-02-09 2024-06-11 義大利商費洛根公司 靶向edb之il-12組合物
CN120365435A (zh) * 2018-08-30 2025-07-25 免疫生物公司 单链嵌合多肽和多链嵌合多肽以及其用途
EP3843788A1 (en) 2018-08-30 2021-07-07 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
CN112996805A (zh) 2018-08-30 2021-06-18 Hcw生物科技公司 多链嵌合多肽和其用途
EP3660039A1 (en) 2018-11-30 2020-06-03 Philogen S.p.A. Il2 immunoconjugates
WO2020070150A1 (en) 2018-10-02 2020-04-09 Philogen S.P.A Il2 immunoconjugates
MX2021007283A (es) 2018-12-18 2021-07-15 Navigo Proteins Gmbh Proteinas de union especificas del folr1 novedosas para diagnostico y tratamiento del cancer.
CN113557242A (zh) * 2019-02-01 2021-10-26 得克萨斯大学体系董事会 用于治疗癌症的修饰的il-12 t细胞疗法
US12583888B2 (en) 2019-02-04 2026-03-24 University Of Tartu Bi-specific extracellular matrix binding peptides and methods of use thereof
CN111848811B (zh) * 2019-04-27 2024-10-01 张晋宇 一种蛋白质异二聚体及其用途
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
JP7713393B2 (ja) 2019-06-21 2025-07-25 イミュニティーバイオ インコーポレイテッド 多鎖キメラポリペプチドおよびその使用
EP4103599A1 (en) 2020-02-11 2022-12-21 HCW Biologics, Inc. Methods of activating regulatory t cells
US12115191B2 (en) 2020-02-11 2024-10-15 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
KR20220140535A (ko) 2020-02-11 2022-10-18 에이치씨더블유 바이올로직스, 인크. 크로마토그래피 수지 및 이의 용도
AU2021257594B2 (en) * 2020-04-14 2024-02-15 Philogen S.P.A. Dosage units and regimen, uses, methods or formulations of compositions comprising a recombinant protein comprising interleukin-12 and an antibody binding the extra-domain B of fibronectin
EP4143231A1 (en) 2020-04-29 2023-03-08 HCW Biologics, Inc. Anti-cd26 proteins and uses thereof
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
US20230399371A1 (en) * 2020-10-29 2023-12-14 Proviva Therapeutics (Hong Kong) Limited Il-12 compositions and methods of use thereof
JP7690131B2 (ja) 2022-01-04 2025-06-09 フィロジェン ソチエタ ペル アツィオーニ Ｉｌ－１２を含むイムノサイトカインとキナーゼ阻害剤の組合せ
EP4507711A1 (en) 2022-04-13 2025-02-19 ImmunityBio, Inc. Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder
CA3266566A1 (en) 2022-09-06 2024-03-14 Philochem Ag MULTIVALENT FIBROBLAST ACTIVATING PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS
WO2026003203A1 (en) 2024-06-27 2026-01-02 Philogen S.P.A. Combination of an immunocytokine comprising targeted il2 and a jak inhibitor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2590912T3 (es) * 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Int Arch Allergy Immunol 1992;98:279-285 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019190022A1 (ko) * 2018-03-30 2019-10-03 한국과학기술원 단백질-단백질 결합체를 형성 매개 펩타이드 및 이를 이용한 단백질-단백질 결합체 형성 방법

Also Published As

Publication number Publication date
CA2607954A1 (en) 2006-11-16
CN101258162A (zh) 2008-09-03
EP1891102A2 (en) 2008-02-27
BRPI0609100A2 (pt) 2010-02-17
US8455625B2 (en) 2013-06-04
EA200702460A1 (ru) 2008-06-30
ES2341126T3 (es) 2010-06-15
EP1891102B1 (en) 2010-03-03
WO2006119897A2 (en) 2006-11-16
MX2007013875A (es) 2008-01-28
AU2006246061A1 (en) 2006-11-16
EA011992B1 (ru) 2009-06-30
DE602006012667D1 (de) 2010-04-15
HK1113579A1 (en) 2008-10-10
US20090035255A1 (en) 2009-02-05
JP2008543278A (ja) 2008-12-04
ATE459648T1 (de) 2010-03-15
WO2006119897A3 (en) 2007-03-15
KR20080009161A (ko) 2008-01-24

Similar Documents

Publication Publication Date Title
KR101281208B1 (ko) 피브로넥틴 ｅｄ-ｂ에 대한 항체 ｌ１９ 및 인터루킨１２의 융합 단백질
CN109942712B (zh) 抗pd-l1/vegf双功能抗体及其用途
US11274133B2 (en) IL2 and TNF immunoconjugates
EP2027153B1 (en) Dimeric molecular complexes
JP3865802B2 (ja) 免疫抱合体ｉｉ
EP1514934B1 (en) Biosynthetic binding protein for cancer marker
RU2758139C2 (ru) Иммуноконъюгаты il2 и мутантного tnf
KR20230061392A (ko) 수용체 쌍형성과 관련된 조성물 및 방법
JP6735822B2 (ja) Ｉｌ２２免疫コンジュゲート
US20200270322A1 (en) Novel interleukin 4 immunoconjugates
WO2018166468A1 (zh) IgG样长效免疫融合蛋白及其应用
US20230312682A1 (en) SIRPalpha-FC FUSION PROTEIN
KR20250166188A (ko) Tnfr2 결합 폴리펩타이드 및 이의 용도의 방법
KR20220047982A (ko) 암의 치료를 위한 인테그린-표적화 노틴-fc 융합 및 항-cd47 항체의 조합물
US12122813B2 (en) Fusion protein comprising an antigen binding domain and a cytokine trimer domain
HK1113579B (en) Fusion protein of antibody l19 against fibronectin ed-b and interleukin 12
KR20250139900A (ko) 결합 분자
CN121949568A (zh) Il-2变体与pd-1抗体及vegf受体融合蛋白及其应用
BR122024016283A2 (pt) Moléculas de ligação a il27ralfa, seus usos, sequência de ácido nucleico, vetor recombinante viral ou não-viral, célula hospedeira, kits, e composição farmacêutica

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20160510

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20170607

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20180509

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20190507

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240627

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240627